

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2015/089461 A1

(43) International Publication Date

18 June 2015 (18.06.2015)

WIPO | PCT

(51) International Patent Classification:

A61K 8/66 (2006.01) A61Q 5/00 (2006.01)

(21) International Application Number:

PCT/US2014/070126

(22) International Filing Date:

12 December 2014 (12.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/915,988 13 December 2013 (13.12.2013) US

(71) Applicant: RESTORSEA, LLC [US/US]; 300 East 93rd Street, Suite 42A, New York, New York 10128 (US).

(72) Inventors: ALABATA, Enrique P.; 21019 Reynolds Drive, Apt. C, Torrance, California 90503 (US). PAO, Patricia S.; 300 East 93rd Street, Suite 42A, New York, New York 10128 (US).

(74) Agent: FRASER, Janis, K.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2015/089461 A1

(54) Title: EXFOLIATIVE HAIR RETENTION-PROMOTING FORMULATION

(57) Abstract: A formulation or a pair of formulations is provided that includes a hair retention-promoting substance and an enzyme that is a peptidase or a lipase and that, when applied to a human scalp, has exfoliating activity. The substance and the enzyme are present in an aqueous carrier having a pH that maintains activity of the enzyme. A process of promoting hair retention on the scalp of a subject is provided in which a hair retention-promoting substance is topically administered to the scalp after, or in concert with, exfoliation of the scalp with an enzyme.

EXFOLIATIVE HAIR RETENTION-PROMOTING FORMULATION

RELATED APPLICATIONS

[0001] This application claims priority benefit of United States Provisional Application 5 Serial Number 61/915,988, filed 13 December 2013, the contents of which are hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] The present invention in general relates to a formulation for promoting hair retention, and in particular to a formulation and process for the use thereof to provide a more 10 efficient usage of follicle health-promoting agents.

BACKGROUND OF THE INVENTION

[0003] Numerous plant extracts and pharmaceuticals have been identified as promoting overall hair follicle health and even promoting hair retention during a follicle rest period. Unfortunately, some users of such products are dissatisfied by the results obtained with such 15 conventional products. Dissatisfaction may occur even in instances when the formulation achieves good results *in vitro* as well as under controlled clinical studies.

[0004] There has been considerable research effort expended to understand the biochemistry of hair retention and to develop compounds promoting hair retention. Unfortunately, there have not been commensurate advances in the development of delivery systems for the transport of 20 topically administered compounds into contact with target cells within the hair follicle in general, and in particular, to the follicle basal cells.

[0005] The anatomy of the hair follicle includes the outermost layer of corneum stratum that has dead and dying dermal cells that form a constriction around the protruding hair shaft. Sebaceous secretions also coat the hair shaft and render the path a topical hair retention agent 25 must take to reach the follicle physically blocked and hydrophobic. Prior art attempts to administer active agents to the follicle basal cells using emulsions have met with limited success owing to the user displeasure with the application of this type of vehicle to the scalp. In addition, emulsions are known to change topical delivery kinetics of active agents (S.Y. E. Hou et al. “Phase volume and partitioning effects on drug delivery from topical emulsions”; International 30 Journal of Pharmaceutics, 66 (1990) 79-85).

[0006] Thus, there exists a need for an exfoliating, hair retention-promoting formulation to more efficiently deliver hair retention-promoting agents to the hair follicle. There also exists a need for such a formulation that is an aqueous solution or suspension.

SUMMARY OF THE INVENTION

[0007] A formulation is provided that includes a hair retention-promoting substance and an enzyme that is a peptidase or lipase, where the enzyme is active in exfoliating a human scalp.

5 The substance and the enzyme are present in an aqueous carrier having a pH that maintains activity of the enzyme.

[0008] A process is provided for enzymatically exfoliating the scalp of a subject for the purpose of promoting hair retention on the subject's scalp. A hair retention-promoting substance is topically administered to the scalp of the subject after, or in concert with, the exfoliation of the 10 scalp. A kit is also provided for performing the process with a first exfoliating phase and a second hair retention-promoting phase, where the two formulations are packaged separately; or alternatively the kit may contain a combined formulation containing both the exfoliating enzyme and the hair retention-promoting substance. The kit also contains instructions for using the components to achieve the desired hair retention.

15

DESCRIPTION OF THE INVENTION

[0009] The present invention has utility in promoting hair retention. Whether scalp exfoliation precedes administration of a hair retention-promoting substance, or the two steps are carried out together, e.g., by administration in a formulation containing both the exfoliating agent 20 and the hair retention-promoting substance, enhanced hair retention promotion is accomplished, as compared to administration of the hair retention-promoting substance without exfoliation.

[0010] Without intending to be bound to a particular theory, exfoliation associated with mechanical abrasion or chemical peeling causes inflammation to the scalp that appears to counteract many of the benefits associated with inventive exfoliation. Chemical peel exfoliation 25 is most often associated with the usage of compounds illustratively including glycolic acid and retinoic acid. Instead, the present invention relies on an enzymatic scalp exfoliant that allows hair retention promoting substance to penetrate around the hair fiber to the papilla. Limiting of inflammation associated with exfoliation appears to promote hair retention promoting substance efficacy.

30 [0011] It is to be understood that, in instances where a range of values is provided herein, the range is intended to encompass not only the end point values of the range, but also individual intermediate values and intermediate ranges within the range. By way of example, a recited range of from 1 to 4 is intended to include not only 1-4, but also 1, 2, 3, 4, 1-2, 1-3, 2-4, and 3-4.

[0012] According to the present invention, an active enzyme is provided that has an

exfoliating effect on human corneum stratum. The active enzyme is in an aqueous carrier that maintains activity of the enzyme during storage. Peptidase enzymes, lipase enzymes and combinations thereof are active enzymes in an inventive formulation and illustratively include trypsin, bromelain, papain, proteins active in natural degrading of egg zona (synonymously referred to herein as egg hatching active proteins), and combinations thereof. Specific egg hatching active proteins operative herein include fish spawn proteins such as zonase (a serine protease) and choriolysin (a zinc protease). It is appreciated that the quantity of active protein present depends on factors illustratively including aqueous carrier pH, enzyme specificity, enzyme activity, carrier viscosity, and enzyme half-life.

10 [0013] As used herein, a peptidase is defined as an enzyme that catalyzes hydrolysis of a peptide bond that links two amino acids together in a polypeptide chain. The term "peptidase" is used herein synonymously with "protease" and "proteinase".

15 [0014] A fish spawn protein isolate, for example, includes a zonase, a leukolectin, a choriolysin, or a combination thereof, and has the properties detailed in U.S. 6,346,245, col. 4, line 15-col. 5, line 8; U.S. 2009/0274770 A1 [0321]-[0326] and U.S. 2011/0280882 [0157]-[0194]; crude extracts containing such proteins; and combinations thereof. Exemplary sources of fish spawn for protein isolation include roes from sturgeon, salmon, whitefish, vendace, cod, capelin, and burbot. It is appreciated that other sources of egg proteins operative herein include amphibian egg cases such as those of tadpoles and salamanders; reptilian egg cases, and fowl egg cases. Typically, an egg- or, with particularity, fish spawn protein-isolate containing at least 20 one of the above recited proteins constitutes from 0.1 to 10% total weight of an inventive formulation, with 0.00001 to 10 percent of the extract being active protein. To give just one example, a given active protein may constitute 1×10^{-8} to 1×10^{-5} total weight percent of the formulation (i.e., 0.00001 to 10 percent of the extract is the protein, and the extract is 0.1% total 25 weight of the formulation). It is appreciated that the amount of protein present in an inventive cosmetic depends on factors illustratively including miscibility with other components.

30 [0015] The active enzyme in the aqueous carrier is readily applied to the scalp in certain inventive embodiments as a first treatment step. The enzyme produces a non-inflammatory exfoliation in and around the hair follicle. In other inventive embodiments, the active enzyme is part of a single formulation that also contains the hair retention-promoting substance.

[0016] Typical loadings of active enzyme range from 0.000001 to 1,000 enzyme units (U) per liter, where an enzyme unit corresponds to one micromole of substrate converted per minute. For purposes of determining U, an *in vitro* assay can be carried out using an oligopeptide substrate that represents the target protein(s) of corneum stratum. In some embodiments, the

oligopeptide is chromogenic, and cleavage thereof by the enzyme produces a detectable color change. While it is appreciated that aqueous carrier pH is readily tailored to modify peptidase enzymatic activity, typical aqueous carrier pH values range from 6 to 8 for many peptidase enzymes operative herein. Exemplary of peptidases active in this pH range are zonase and trypsin.

[0017] In some embodiments, an inventive formulation includes the peptidase enzyme and a hair retention-promoting substance combined in an aqueous carrier. It is appreciated that an inventive formulation containing both the active enzyme and the hair retention-promoting substance facilitates user compliance, as only a single formulation need be applied. In some 10 embodiments, the formulation (or both formulations, when separate formulations are used) may conveniently be applied as a leave-in spray solution, which also facilitates user compliance.

[0018] Regardless of whether the present invention is practiced as an exfoliating enzymatic step and a separate hair retention-promoting substance step, or if these two steps are combined into one by using a single formulation containing both active ingredients, application to the scalp 15 typically occurs on a regime of once a week, 2-6 days per week, once daily, or even two or three times daily. It is appreciated that, when the two ingredients are applied in separate steps, the timing and frequency of the first can vary from the timing and frequency of the second. By way of example, upon effecting exfoliation with one or more applications of the enzyme, multiple doses of hair retention-promoting substance may be applied (e.g., once per day for multiple days) 20 before the exfoliation step is repeated. It may be sufficient to do only occasional maintenance application of the enzymatic exfoliant.

[0019] As used herein, a hair retention-promoting substance is defined as a substance that promotes hair retention and is a purified organic compound, a natural product extract containing one or more such compounds, or a synthetic compound. The substance may be, for example, an 25 inhibitor of prostaglandin-D2 or an inhibitor of dihydro-testosterone. It is appreciated that many natural product extracts, including some that contain polyphenols, have been shown to be effective in promoting hair retention. Specific hair retention-promoting substances operative herein illustratively include minoxidil, red ginseng extract, hesperidin extract, green pea shoot extracts, synthetic oligopeptides sold under the tradename SymPeptideTM, and combinations thereof. It is appreciated that hair retention-promoting substances are typically used in an 30 inventive formulation from 0.001 to 1 total weight percent, but can be up to 10 total weight percent, e.g., where the extract contains a relatively low concentration of active agent. An inventive formulation is readily formulated as a water based solution or as an emulsion containing an aqueous carrier phase for the enzymes. It is appreciated that some hair retention-

promoting substances are lipophilic, while others are hydrophilic. Lipophilic hair retention-promoting substances are readily formulated as a two-phase formulation with a solvent appropriate for dissolution or suspension of the hair retention-promoting substance. The solvents illustratively include skin-compatible alcohols, ketones, esters, aldehydes, ethers, alkanes, 5 alkenes, alkylated sulfoxides; cyclics of any of the aforementioned; fluorinated analogs of any of the aforementioned; and combinations thereof. Specific solvents for certain hair retention-promoting substances (either single compound or extract) illustratively include water, ethanol, isopropanol, acetone, glycols, alkoxylated glycols, diethyl ether, pentane, hexane, dimethyl sulfoxide, and combinations thereof. In some embodiments, lipophilic hair retention-promoting 10 substances are present in an oil phase of an oil-in-water or water-in-oil emulsion.

[0020] In still other inventive embodiments, an anti-inflammatory agent is included in an enzyme and hair retention-promoting substance combined formulation, or in one or both parts of a two-formulation embodiment (one formulation containing the active enzyme and the other formulation containing the hair retention-promoting substance. Anti-inflammatory agents 15 operative herein illustratively include steroidal anti-inflammatory agents; non-steroidal anti-inflammatory agents; extracts of plants such as turmeric, oregano, garlic, green tea, blueberries, neem, holy basil oil, licorice, ashwaganda, raspberry leaf, St. John's Wort, chamomile, and ginger; omega fatty acids; alpha-linolenic acid; and combinations thereof.

[0021] In still other inventive embodiments, an antioxidant may be included in a mixed 20 enzyme and hair retention-promoting formulation, or in one or both parts of a two-formulation embodiment. Antioxidants operative herein illustratively include alpha lipoic acid, beta-glucan, coenzyme Q10, grape seed extract, oat extract, chamomile, green tea, soybean sterols, superoxide dismutase, vitamin C (e.g., in the form of ascorbyl palmitate, magnesium ascorbyl palmitate, or ascorbic acid 2-gluconate), and vitamin E (e.g., alpha tocopherol or a tocotrienol), 25 and combinations thereof. It is appreciated that a number of anti-inflammatory agents possess antioxidant properties. The formulations of the invention that include such an anti-inflammatory agent may also include a separate antioxidant compound.

[0022] In still other embodiments of the present invention, a formulation or a single 30 component thereof is provided that is essentially free of synthetic compounds. In still other embodiments, a formulation or a single part thereof is provided that is certified organic.

[0023] In certain embodiments, a single, mixed formulation is provided containing both the peptidase enzyme and the hair retention-promoting substance in an aqueous solution that is suited for use as leave-in scalp spray or wash. When the aqueous carrier evaporates, it leaves the active enzyme and substance in contact with the scalp.

[0024] To maintain peptidase or lipase enzyme activity, a process of formulation includes the buffering of any constituent phase containing the enzyme(s) to a pH of between 5 and 8 prior to introduction of enzyme to that phase. Buffering is commonly practiced in the field and includes the addition of an acid, a base, a salt of an acid, or a combination thereof to equilibrate an aqueous solution or aqueous phase of an emulsion to a desired pH. It is appreciated that pH measurement is routine. pH may be measured quantitatively via volumetric titration or with potentiometric electrodes such as those commercially available from Thermo Fisher Scientific (Waltham MA, USA), or qualitatively with litmus paper kits.

[0025] Biocides are present in some inventive embodiments. A biocide helps maintain product quality by inhibiting growth of microorganisms introduced during formulation of the product or during use thereof, particularly when the product is packaged in multiple-use packaging, so is exposed to continual microbial seeding from the environment or the user. An inventive formulation may optionally include a broad spectrum biocide and/or a combination of biocides. A broad spectrum biocide is defined herein as having activity against Gram positive bacteria, Gram negative bacteria, and fungi associated with a healthy human subject. Biocides operative herein illustratively include benzoic acid, parabens, salicylic acid, carbolic acid, sorbic acid, alkyl p-hydroxybenzoates, p-chlorometacresol, hexachlorophene, benzalkonium chloride, chlorohexidine chloride, trichlorocarbanilide, phenoxyethanol, acylsarcosines, glutathione, malic acid, tartaric acid, ascorbic acid, ascorbic acid glucoside, ascorbates, essential plant oils, mutacin proteins, and combinations thereof. In certain embodiments of the present invention, only naturally-derived biocides—i.e., biocides found in nature or extracted from a natural source—are present. Naturally derived biocides illustratively include fermentation filtrates such as those of *Lactobacillus*, *Streptococcus mutans*, and *Leuconostoc*; bisabolol; eucalyptol; thymol; inositol; saponins; and natural extract of plants, such as Japanese honeysuckle (*Lonicera japonica*), yangti (*Rumex japonicus*), kushen (*Sophora flavescens*), candelilla, wild oregano, orange, sage, manio, common mallow, chuanxiong (*Cnidii officinale* Makino), Japanese green gentian (*Swertia japonica* Makino), bisabolol, thyme, dangui (*Angelica sinensis*), orange peel, birch, field horsetail, dishcloth gourd, horse chestnut tree, creeping saxifrage (*Saxifrage stolonifera*), arnica, lily, mugwort, peony, aloe, gardenia, as well as those detailed in M. M. Cowan, *Clinical Microbiology Reviews*, 12(4) Oct. 1999, p. 564–582; or combinations thereof. Such extracts are obtained by procedures detailed in *Clinical Microbiology Reviews*, 12(4) Oct. 1999, pages 573–574, often using a hydrophilic organic solvent such as a C₁-C₈ alcohol, polyhydric alcohols, water, and aqueous alcohols. In specific embodiments, Japanese honeysuckle, phloretin (derived from apples), and/or galangin (e.g., from *Alpinia officinarum* or

Helichrysum aureonitens) are used as naturally derived biocides, each alone or in combination. It is appreciated that in addition to biocide properties, a natural extract often imparts a fragrance to an inventive formulation or phase thereof. In specific embodiments, a biocide may be present in the formulation(s) from 0.1 to 5 total weight percent. It is appreciated that quantities of biocides beyond 5 total weight percent may be included as desired. It is further appreciated that in some instances the inclusion of transition metal ions is used to reduce enzymatic activity of microbes.

5 [0026] In still other embodiments of the present invention, the formulation containing the exfoliative enzyme may be provided in a sterile form. Sterilization may be accomplished by any standard means that does not denature or degrade the enzyme. While heat or radiation may be possible, more typically size exclusion sterilization (i.e., filtration) will be used to remove contaminating bacteria and in some cases viruses from a solution containing the enzyme, or from the final formulation itself. It is appreciated that single-use packages are best suited for maintaining sterility of the sterilized formulation, as airborne microbes or microbes associated with the subject tend to infiltrate an opened package.

10 15 [0027] In some embodiments, the formulation(s) are packaged in a container having a pump atomizer. In other embodiments, the container is a pressurized spray can, a squeeze bottle or squeeze tube, a bottle with an applicator (separate or attached), a single-use vial, or any other appropriately configured container. The container may be formed of plastic, glass, or metal.

20 [0028] One part and two-part versions of the present invention are illustrated in exemplary form in Tables 1 and 2, respectively.

[0029] Table 1. Typical ranges of ingredients in a one-part formulation, where the percentages are total weight percent.

	Deionized water	Remainder
25	Exfoliating enzyme solution	0.001 to 10%
	Hair retention-promoting substance	0.001 to 10%
	Antioxidant	0 to 5%
	Anti-inflammatory agent	0 to 5%
	pH adjuster/buffer	0 to 5%
30	Biocide	0.1 to 10%
	Fragrance	0 to 5%
	Citric acid	0 to 1%

[0030] Table 2. Typical ranges of ingredients in each of the two parts of a dual-formulation embodiment, where the specified percentages denote total weight percent.

Part 1-Exfoliator

5	Deionized water	Remainder
	Exfoliating enzyme solution	0.001 to 10%
	Antioxidant	0 to 5%
	Anti-inflammatory agent	0 to 5%
	pH adjuster/buffer	0 to 5%
10	Biocide	0.1 to 10%
	Fragrance	0 to 5%
	Vitamin(s)	0 to 1%

15 Part 2-Hair retention promoter

15	Deionized water/solvent	Remainder
	Hair retention-promoting substance	0.001 to 10%
	Antioxidant	0 to 5%
	Anti-inflammatory agent	0 to 5%
20	pH adjuster/buffer	0 to 5%
	Biocide	0.1 to 10%
	Fragrance	0 to 5%
	Vitamin(s)	0 to 1%

25 [0031] It has been found that, as the active enzyme is prone to degradation through exposure to heat and mechanical agitation, the manner in which the formulation containing the enzyme is prepared is important to maintaining enzymatic activity. For example, one can add the enzyme late in the formulation process, or one can minimize these sources of energy when the enzyme is present, or both.

30 [0032] In some embodiments, the inventive formulation is in the form of an emulsion. Without intending to be bound to a particular theory, an emulsion is well suited to wet the hair cortex, which tends to be lipophilic owing to secretion from sebaceous glands surrounding the hair follicle.

[0033] The minority phase components of an oil-in-water emulsion illustratively include oils, waxes, esters, ethers, butters, glycerides, or combinations thereof. The majority phase components of an oil-in-water emulsion may include, besides water: aqueous salts, humectants, and various water soluble materials as detailed above. An emulsifier for such a system may be 5 selected from ionic surfactants, non-ionic surfactants and also including lecithin, liposomes, and oleosomes. Other non-essential additives are readily provided that include viscosity modifiers, emulsion stabilizers, fragrances, and the like. In specific embodiments, the oil-in-water emulsion has a pH value of 5 to 8. If certain embodiments, the oil-in-water emulsion has a pH value of 6 to 10 7, e.g., 6.5 to 6.8. It is appreciated that including an enzyme in an aqueous segment of a water-in-oil emulsion serves to stabilize the enzyme against storage degradation.

[0034] The water-in-oil emulsion or a water-in-silicone emulsion varies the relative quantities of minority and majority phase components and preferably relies on non-ionic surfactants and silicone derivatives as emulsifiers. Viscosity modifiers and/or emulsion stabilizers illustratively include water soluble salts, gums, waxes, and combinations thereof. In 15 specific embodiments, the inner phase has a pH of 4 to 8. It is appreciated that various vitamins such as vitamin B complexes, vitamin E, vitamin K, ascorbic acid derivatives such as ascorbic acid glucosides, E-O-alkyl ascorbic acid, and ascorbate phosphates are readily provided in one or both of the aforementioned emulsion phases or provided as a separate third phase. The vitamin(s) may be in addition to the anti-oxidant and/or anti-inflammatory ingredients described above.

[0035] An inventive emulsion formulation is readily formed by combining premixed phases as detailed above or alternatively all such components are intermixed in sequence conventional to the art as a unified mixture—provided that, in a formulation containing active enzyme, care is taken not to subject the enzyme to excess heat or shear during the mixing process (if the enzyme is sensitive to same).

[0036] It should be appreciated that other conventional base formulations are readily adjusted as detailed herein to stabilize the active exfoliative enzyme. A variety of conventional base formulations are provided in E. W. Flick, “Cosmetic and Toiletry Formulations”, 2nd Ed., Vol. 8; 2001, Noyes Publications, Norwich, New York, USA (ISBN 0-1855-1454-9).

[0037] A process of stimulating hair retention on a scalp is also provided. This process 30 includes enzymatically exfoliating the scalp of a subject. In operation, the liquid formulation (solution, emulsion, or suspension) is applied to the subject's scalp and hair roots. This can be done by squirting or dabbing the formulation onto the target area, or by forming a mist with a propellant-based pressurized aerosol spray can or a manual spray pump equipped with a conventional atomizer nozzle, and directing the mist at the target area. Between 0.1 and

5 milliliters of liquid are sufficient to form a mist on the hair and underlying scalp, but the amount needed to achieve the hair retention effect will depend on factors that include the concentration of the enzyme, the concentration of the hair retention-promoting active agent, and the viscosity of the formulation. The application of the exfoliative enzyme and the application of 5 the hair retention-promoting substance are readily performed as separate steps. Alternatively, one can apply them simultaneously, e.g., using a single formulation that includes both the peptidase enzyme and the hair retention-promoting substance. In instances where the two active agents are applied using separate formulations, it is appreciated that the two formulations can be similar or can be very different. For example, the enzyme will generally be formulated in an 10 aqueous solution or an emulsion with an aqueous phase containing the enzyme. In contrast, the hair retention-promoting substance may be either hydrophilic or lipophilic and so may require a type of formulation different from that used for the enzyme.

15 [0038] In some usage regimens employing dual formulations, the first formulation (containing the active enzyme) is used routinely (e.g., daily) for the first several weeks along with regular application (e.g., daily or twice daily) of the second (hair retention-promoting) formulation; after a degree of exfoliation has been achieved, the first formulation is applied less frequently, for example, only every two or three days, while the frequency of applying the second formulation is maintained. Hair retention improvement is typically noted in two to three months.

20 [0039] The present invention is further illustrated with reference to the following non-limiting examples.

EXAMPLE 1

25 [0040] A process for forming a revitalizing scalp treatment in five steps in an aqueous solution of deionized water is provided. In step A, citric acid, sodium citrate, and a glucoside of ascorbic acid are added in that order to the deionized water in a main vessel, with each ingredient mixed with the water until blended prior to adding the next ingredient. In step B, sodium hydroxide (NaOH) (20%) is added to adjust the pH of the first mixture in the main vessel to between 6.5 to 6.8. In step C, glucosyl hesperidin and red ginseng extract (40% water, 60% 30 butylene glycol and 0.2 % Panax Ginseng Root Extract by weight), are added to the main vessel and mixed in until all solids dissolve and are uniformly blended. In step D, 1,2-hexanediol, pentylene glycol, and a brown algae extract in caprylic/capric triglyceride solvent (the extract containing, in milligrams per 100 grams of solvated extract: palmitic acid 28.2, palmitoleic acid 12.4, stearic acid 6.8, oleic acid 14.7, linoleic acid - (Omega 6) 7.2, a linolenic acid 9.7, omega 3

fatty acids 26.3, cholesterol 47.2, campesterol 45.9, stigmasterol 57.5, and sitosterol 142.8) are premixed in a separate vessel, and then added to the main vessel and mixed until blended. In step E, a salmon egg hatching enzyme solution containing leukolectin(s) or other lectins, choriolysin(s), and zonase (leukolectin content of 0.00068 wt. %, zonase content of

5 0.00034 wt. %, choriolysin content of 0.0000136 wt. %) is added to the main vessel and mixed until blended, forming the final formulation. Table 3 lists the aforementioned ingredients, where percentages are total weight percent.

[0041] Table 3. Exemplary inventive hair retention formulation.

10	Deionized water	Remainder
	Citric acid	0.015%
	Sodium citrate	0.150%
	Ascorbic acid glucoside	0.001%
	Sodium hydroxide (20%)	0.027%
15	Glucosyl hesperidin	1.000%
	Red ginseng extract	3.000%
	1,2-hexanediol	1.000%
	pentylene glycol	5.000%
	Brown algae extract	0.001%
20	Salmon egg hatching protein solution	1.000%
	pH	6.78
	Specific gravity	1.005

25

EXAMPLE 2

[0042] The process of Example 1 is repeated with the addition of a vitamin complex containing in solution vitamins B3, B5, B6, C and E. The amount of the vitamin complex solution added is 2 percent of the final total weight, with a corresponding reduction in the 30 amount of deionized water. The vitamins are present in the vitamin complex solution in amounts varying from 10 to 200 milligrams per 100 grams of vitamin complex solution.

EXAMPLE 3

[0043] A female subject suffering a daily hair loss of on average 52 hairs per day as

measured by drain trap collection, commenced usage of the formulation of Example 1 on a daily basis with aerosol misting of the head with 1 milliliter of solution after routine shampoo and conditioner usage, followed by 5 minutes of dwell time prior to blow drying. After 8 weeks of daily use, daily hair loss was reduced to on average 4.6 hairs per day.

5

EXAMPLE 4

[0044] The method of Example 3 is repeated with the formulation of Example 2, resulting in a daily hair loss of on average 3.4 hairs per day.

10 EXAMPLE 5

[0045] The method of Example 1 is repeated, but with the omission of glucosyl hesperidin from the formulation. A reduction in daily hair loss is noted consistent with that of Example 3.

EXAMPLE 6

15 **[0046]** A clinical trial was conducted with the formulation of Example 1. Subjects were recruited with enrollment criteria that included: subject is female between the ages of 25 and 55 years; subject normally uses shampoo and conditioner; subject has hair length that is sufficient for evaluation, as determined by the cosmetologist; has Skin Type I-IV (ranging from white to moderately brown with skin reaction to sun within the range of “always burns” to “tans with ease”);
20 subject sheds at least 20 hairs at the baseline evaluation; subject agrees to replace their usual hair shampoo and conditioner with the provided materials during the conditioning phase and for the duration of the study; subject agrees to apply the assigned scalp treatment once every other day for the duration of the study; subject agrees to protect the scalp from sun exposure; subject is in generally good health; and subject is dependable and able to follow directions as outlined in the
25 protocol.

[0047] Enrolled subjects were instructed to apply the test material to the scalp every other day during the 24 week use period. Subjects were instructed to refrain from test material use and washing/conditioning the hair the morning of each visit. Subjects were also instructed to refrain from using any shampoos, conditioners, and scalp treatments (other than the materials provided),
30 but were told they may continue styling their hair in the usual manner (i.e. blow dry, flat iron, curling iron) and may use their usual styling products.

[0048] After approximately 4, 8, 12, 16, 20, and 24 weeks of use, subjects returned to the laboratory with unwashed hair, having refrained from test material application on the morning of the visit. At each visit, MEDISCOPE® images of the scalp were obtained as described below.

Visual grading of the hair was performed as described below. A cosmetologist washed and conditioned each subject's hair with Free & ClearTM Shampoo and Conditioner. Wet and dry hair collections were performed as described below.

FotoFinder MEDISCOPE® (FotoFinder Systems, Inc.) Testing Procedure

5 [0049] MEDISCOPE® combines the high resolution of digital photography with the direct capture features of a software archiving system and, in doing so, simplifies the photo-documentation process. Mediscope utilizes a Canon Powershot G10 (14.7 Mega Pixel). This camera takes photos in outstanding quality that can be seen immediately on-screen. The whole imaging process is completely controlled by the software. An overlay feature allows the baseline 10 images to be overlaid onto the live preview images, thus ensuring almost exact repositioning at every visit. One digital image of the scalp (crown of the head) was collected at each visit. The hair of each subject was assessed by a cosmetologist using a modified Visual Analog Scale (VAS) at each visit. The cosmetologist selected a location on the 100mm VAS scale that corresponds with the assessment of hair thickness/volume, in relation to the labeled vertical 15 positions on the scale. The distance between the mark recorded and the left origin of the line was subsequently measured in millimeters, to allow for assignment of a numerical score for the extent of the evaluated parameter.

Hair Collections Procedure

20 [0050] At each visit, the hair was shampooed/conditioned by the cosmetologist at the laboratory using Free & ClearTM Shampoo and Conditioner. Subjects wore a drape (white for dark-haired subjects and black for light-haired subjects). The hair was detangled with a comb or pick, if necessary. The hair was divided into five sections. Each section was combed from root to end for five strokes, using a wide tooth comb. Any hair shed onto the drape or in the sink was collected and counted. The hair was then finger-blown dry. Once the hair was dry, the hair was 25 divided into five sections. Each section was combed from root to end for five strokes, using a wide tooth comb. Any hair shed onto the drape was collected and counted.

DATA ANALYSIS

30 [0051] Total hair counts at each visit (wet and dry combined) and scores for clinical grading of hair appearance were listed for each subject and treatment and were analyzed statistically. Analysis of Variance with 2 factors (time as a fixed effect and subject as a random effect) was followed by a Dunnett's test applied to determine the differences between baseline and each post-treatment interval (Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24). If the residuals of the Analysis of Variance were not distributed normally (Shapiro-Wilk test at the threshold of 1%), this analysis was carried on ranks.

[0052] Change from baseline was calculated at each post-treatment interval for the above mentioned parameters. Analysis of variance followed by Tukey multiple comparison post hoc test was applied to determine the differences in change from baseline between test formulation vs. placebo control.

5 [0053] The study results are provided in Tables 4 and 5. The values for subjects treated with the Example 1 formulation improved over time. Given the tolerance and low toxicity of a formulation of Example 1, usage in perpetuity is contemplated.

Table 4. Mean VAS Score for hair thickness/volume for at various time points

Mean VAS Score for Hair Thickness/Volume							
Treatment	Baseline	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
Example 1	51	54	54	55	54	57	58

10

Table 5. Mean total hair loss count at various time points.

Mean Total Hair Loss Count							
Treatment	Baseline	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
Example 1	67	56	47	38	29	28	27

Any patents or publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to

15 be incorporated by reference.

CLAIMS

1. A formulation for promoting hair retention, the formulation comprising:
 - a hair retention-promoting substance;
 - one or more enzymes selected from a peptidase, a lipase or a combination thereof;5 and
 - an aqueous carrier.
2. The formulation of Claim 1, wherein said hair retention-promoting substance is an extract of red ginseng.
- 10 3. The formulation of Claim 1, wherein said hair retention-promoting substance is hesperidin or glucosyl hesperidin.
4. The formulation of Claim 1, wherein said hair retention-promoting substance is a dihydro-testosterone inhibitor.
- 15 5. The formulation of Claim 1, wherein the one or more enzymes comprise a peptidase.
6. The formulation of Claim 5, wherein the peptidase is trypsin or an egg hatching protein.
7. The formulation of any one of Claims 1 through 6, wherein the one or more enzymes comprise an egg hatching protein that is choriolysin.
- 20 8. The formulation of any one of Claims 1 through 6, wherein the one or more enzymes comprise an egg hatching protein that is zonase.
9. The formulation of any one of Claims 1 through 6, further comprising a lectin protein or a leukolectin protein.
- 25 10. The formulation of any one of Claims 1 through 6, further comprising an antioxidant that is not the hair retention-promoting substance nor the one or more enzymes.
11. The formulation of any one of Claims 1 through 6, further comprising a biocide that is not the hair retention-promoting substance nor the one or more enzymes.
12. The formulation of any one of Claims 1 through 6, wherein said aqueous carrier

has a pH between 4 and 8.

13. The formulation of Claim 1, further comprising an anti-inflammatory agent that is not the hair retention-promoting substance nor the one or more enzymes.

14. The formulation of Claim 13, wherein the anti-inflammatory agent is a non-
5 steroidal anti-inflammatory drug.

15. A process of promoting hair retention on a scalp of a subject, the process comprising topically administering to the scalp of the subject:

an enzyme that promotes exfoliation; and
a hair retention-promoting substance that is not the enzyme.

10 16. The process of Claim 15, wherein administering said enzyme occurs prior to administering said hair retention-promoting substance.

17. The process of Claim 15, wherein said enzyme and said hair retention-promoting substance are administered simultaneously.

15 18. The process of any of Claims 15 to 17, wherein said enzyme and said hair retention-promoting substance are administered at least three times a week for at least one month.

19. A kit for promoting hair retention on a subject's scalp, the kit comprising packaging containing:

20 a first formulation comprising one or more exfoliating enzymes selected from a peptidase, a lipase, or a combination thereof;
a second formulation separate from the first and comprising a hair retention-promoting substance that is not the one or more enzymes; and
instructions for administering the first and second formulations to the scalp of a subject.

25

20. The kit of Claim 19, wherein the second formulation comprises a hydrophobic phase.

30 21. The kit of Claim 19 or 20, wherein the second formulation is an oil-in-water or water-in-oil emulsion.

22. The kit of Claim 19 or 20, wherein at least one of the first and second formulations is in a container equipped with a pump spray.

5 23. The kit of any one of Claims 19 to 20, wherein the first formulation is in a sterile container.

24. A kit for promoting hair retention on a subject's scalp, the kit comprising packaging containing:

10 a formulation comprising (a) one or more exfoliating enzymes selected from a peptidase, a lipase, or a combination thereof in an aqueous carrier; and (b) a hair retention-promoting substance; and
instructions for administering the formulation to the scalp of a subject.

15 25. The kit of Claim 24, wherein the formulation is an aqueous solution or suspension.

26. The kit of Claim 24, wherein the formulation is an emulsion.

27. The kit of any one of Claims 24 to 26, wherein the formulation is in a container equipped with a pump spray.

20 28. The kit of any one of Claims 24 to 26, wherein the formulation is in a sterile container.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2014/070126

A. CLASSIFICATION OF SUBJECT MATTER

A61K 8/66(2006.01)i, A61Q 5/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 8/66; A61K 47/14; A61K 36/906; A61K 8/64; A61K 47/10; A61F 13/02; A61K 38/46; A61B 17/50; A61K 8/97; A61K 7/00; A61Q 5/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & Keywords: hair retention-promoting substance, enzyme, aqueous carrier, kit


C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00-07627 A2 (JOHNSON & JOHNSON CONSUMER COMPANIES, INC.) 17 February 2000 See abstract; page 21, line 29; claims 1 and 20-22.	1-14, 19-28
Y	US 6416769 B1 (VROMEN, JACOB) 9 July 2002 See abstract; claims 1 and 12; column 2, lines 1-2; claims 1 and 6-8; example 1.	1-14, 19-28
Y	US 2012-0123442 A1 (LARSEN, SANNE HARTELIUS et al.) 17 May 2012 See abstract; paragraphs [0015]-[0016]; claims 1 and 12.	6-9
Y	US 2006-0257386 A1 (ZIMMERMAN, AMY C. et al.) 16 November 2006 See abstract; claims 53 and 60.	19-28
A	WO 2013-112569 A1 (RESTORSEA, LLC.) 1 August 2013 See abstract; claims 1, 13-15, 21 and 41.	1-14, 19-28

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
30 March 2015 (30.03.2015)Date of mailing of the international search report
31 March 2015 (31.03.2015)Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City, 302-701,
Republic of Korea
Facsimile No. +82 42 472 7140Authorized officer
HEO, Joo Hyung
Telephone No. +82-42-481-8150

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2014/070126**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 15-18
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 15-18 pertain to a method for treatment of the human by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2014/070126

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 00-07627 A2	17/02/2000	AR 019997 A1 AU 1999-56695 A1 AU 5669599 A CA 2339231 A1 EP 1104280 A2 JP 2003-521452 A US 2002-0048558 A1 US 6284234 B1 US 6419913 B1 WO 00-07627 A3 WO 00-07627 A8	27/03/2002 28/02/2000 28/02/2000 17/02/2000 06/06/2001 15/07/2003 25/04/2002 04/09/2001 16/07/2002 17/08/2000 08/02/2001
US 6416769 B1	09/07/2002	AU 2001-50023 A1 AU 250023 B2 CA 2401391 A1 EP 1265584 A1 EP 1265584 A4 WO 01-66066 A1	17/09/2001 18/08/2005 13/09/2001 18/12/2002 07/05/2003 13/09/2001
US 2012-0123442 A1	17/05/2012	CN 102471766 A EP 2454366 A2 RU 2012105529 A WO 2011-006508 A2 WO 2011-006508 A3 WO 2011-006508 A8	23/05/2012 23/05/2012 27/08/2013 20/01/2011 14/04/2011 08/03/2012
US 2006-0257386 A1	16/11/2006	JP 2007-508320 A JP 2008-518042 A KR 10-2006-0108665 A TW I381847B US 2006-0257509 A1 US 2007-0254021 A1 US 2010-0285080 A1 US 7758878 B2 US 7959953 B2 US 8697099 B2 WO 2005-034891 A2 WO 2005-034891 A3 WO 2006-041526 A1	05/04/2007 29/05/2008 18/10/2006 11/01/2013 16/11/2006 01/11/2007 11/11/2010 20/07/2010 14/06/2011 15/04/2014 21/04/2005 19/05/2005 20/04/2006
WO 2013-112569 A1	01/08/2013	AP 201407818 D0 AU 2013-212251 A1 CA 2829932 A1 CN 103687586 A EP 2691069 A1 IL 233530 D0 JP 2014-512393 A KR 10-2013-0133285 A MA 35247 B1	31/07/2014 26/09/2013 01/08/2013 26/03/2014 05/02/2014 31/08/2014 22/05/2014 06/12/2013 03/07/2014

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2014/070126

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		SG 194972 A1 US 2013-336948 A1 US 2014-072547 A1	30/12/2013 19/12/2013 13/03/2014